Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPK 001
- Development stage
- Preclinical
- Lead developer
- EPIK Biosciences
- Modality
- Small Molecules
- Administration
- Intravenous, Sublingual, Topical
01
Overview
EPK 001 is a preclinical-stage, ketamine-based synergistic combination small molecule medicine being developed by EPIK Biosciences. It is designed to modulate NMDA receptor signaling to treat central nervous system (CNS) disorders, including depression, anxiety disorders, post-traumatic stress disorder (PTSD), opioid use disorder, and chronic and severe pain. EPIK Biosciences utilizes a platform focused on NMDA receptor modulation and co-delivery formulations of FDA-approved compounds to improve efficacy, durability, and patient accessibility, with plans to pursue the 505(b)(2) regulatory pathway.
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on EPK 001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EPK 001.